Patents Examined by Erin M Bowers
  • Patent number: 12285470
    Abstract: Tie present invention relates to compositions and methods of influencing autophagy by modulating TRIM (tripartite motif containing) proteins, especially TRIM 8, TRIM: 10, TRIM 16, TRIM 19 and/or TRIM 51 (preferably TRIM 16} and galectins, especially galectins 3 m order to influence autophagy and treat a number of disease states and/or conditions which are mediated and/or influenced by autophagy, including inflammatory disease states and/or conditions, including a microbial infection such as a Mycobacterium infection, among numerous others, an inflammatory disorder, a lysosomal, storage disorder, an immune disorder, a neurodegenerative disorder and a cancer.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: April 29, 2025
    Assignee: UNM RAINFOREST INNOVATIONS
    Inventor: Vojo Deretic
  • Patent number: 12274720
    Abstract: Provided herein are methods for preventing or treating diseases, said methods comprising (i) inhibiting entry of bacteriophages and/or component(s) thereof into microbiota, bodily fluid(s) or tissue(s) of the mammals and/or (ii) inactivating or modifying bacteriophages and/or component(s) thereof present in microbiota, bodily fluid(s) or tissues of the mammals and/or (iii) inactivating or modifying bacteriophages and/or component(s) thereof in one or more of food, drinking water, water for washing, water for air humidification, air, or habitat object of the mammals.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: April 15, 2025
    Inventors: Viktor Veniaminovich Tets, Georgy Viktorovich Tets
  • Patent number: 12276667
    Abstract: Disclosed herein are methods for solubilizing and isolating nuclear proteins from cells.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: April 15, 2025
    Assignee: Altius Institute for Biomedical Sciences
    Inventors: Alexander Federation, John Stamatoyannopoulos
  • Patent number: 12258589
    Abstract: Provided is a glycated hemoglobin oxidase with small measurement error or without deviation of the measured value from the true value regarding a sample containing glycated abnormal hemoglobin. Provided are a glycated hemoglobin oxidase comprising an amino acid sequence in which the amino acid at the position corresponding to position 113, 109, 106, or 102 of the amino acid sequence of SEQ ID NO: 1 is substituted with an amino acid other than a positively-charged amino acid, such as glutamic acid, alanine, or aspartic acid as well as a method and a reagent kit for measurement of glycated hemoglobin using such glycated hemoglobin oxidase. The glycated hemoglobin is capable of reacting with various genotypes and enables highly accurate measurement of glycated hemoglobin in a sample containing glycated abnormal hemoglobin.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: March 25, 2025
    Assignee: Kikkoman Corporation
    Inventor: Atsushi Ichiyanagi
  • Patent number: 12258547
    Abstract: A cell culture plate includes one or more cell culture well(s) including at least one barrier for dividing the well into at least two compartments, wherein the barrier includes nanofibrillar cellulose hydrogel, and a method for the preparation thereof. A method for detecting a substance is also disclosed.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: March 25, 2025
    Assignee: UPM-KYMMENE CORPORATION
    Inventors: Markus Nuopponen, Lauri Paasonen, Marika Mannerström, Tuula Heinonen, Tarja Toimela
  • Patent number: 12246041
    Abstract: A medicament is provided including, for example, a dried particulate mixture of decellularized amniotic material and a powdered, lyophilized mixture of cervical mucus plug. The medicament may be useful in treating infectious disease, for example, viral diseases, in promoting repair of tissue and halting disease progression.
    Type: Grant
    Filed: May 12, 2023
    Date of Patent: March 11, 2025
    Assignee: ANICELL BIOTECH, LLC
    Inventors: Brandon Ames, Christopher A. Bradley, Tammi Epp
  • Patent number: 12235217
    Abstract: A method for analyzing a sample includes introducing the sample into a vessel including a cation-exchange resin, where the cation-exchange resin has a high affinity to one or more interferent species in the sample, directing the sample through the cation-exchange resin to thereby capture one or more interference species in the cation-exchange resin to purify the sample, and releasing the purified sample from the vessel. Additionally, a method for analyzing a sample includes receiving an image depicting a diagnostic test region and a color reference chart, converting a test region image portion of the image to an analytical color space, determining first and second coordinate values characterizing the test region image portion in the analytical color space, and providing a quantitative measurement of an analyte of interest in the sample based on the first and/or second coordinate values and a predictive formula based on the color reference chart.
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: February 25, 2025
    Assignee: Scanwell Health, Inc.
    Inventors: Yunyuan Vivian Wang, Aaron Alexander Rowe, Hui-Ling Koh, Stephen L. Chen, K C Chen
  • Patent number: 12235260
    Abstract: The present disclosure relates to systems and methods for analysis of proteins, more in particular to nanopore systems, devices and methods for single-molecule protein analysis and sequencing. Provided is a method for translocating a target protein through a nanopore, the nanopore being comprised in a membrane separating a fluidic chamber of a nanopore system into a cis side and a trans side, comprising: (a) allowing a protein translocase in solution to capture and form a complex with the target protein to be translocated; (b) contacting the translocase-target protein complex with the cis side of the nanopore and allowing for translocation of the target protein to the trans side; wherein the nanopore system has a cis to trans electro-osmotic force (EOF) resulting from a large net ionic current flow cis-to-trans relative to the total ionic current flow, so that the target protein is captured in the nanopore with on top of the nanopore the translocase controlling the translocation.
    Type: Grant
    Filed: December 22, 2023
    Date of Patent: February 25, 2025
    Assignees: Rijksuniversiteit Groningen, Portal Biotech Limited
    Inventors: Giovanni Maglia, Shengli Zhang, Andrew Heron
  • Patent number: 12234499
    Abstract: Provided herein are compositions, methods, systems and/or kits for detection of bacteria expressing enzymes that confer resistance to antimicrobial agents. Certain embodiments of the compositions, methods, systems and/or kits of the present disclosure are related to detection of carbapenemase-producing gram negative bacteria. Certain embodiments of the compositions, methods, systems and/or kits of the present disclosure are related to detection of Ambler Class A, B and/or D carbapenemase-producing enteric and non-fermenting gram negative rod bacteria.
    Type: Grant
    Filed: March 25, 2022
    Date of Patent: February 25, 2025
    Assignee: BECTON, DICKINSON AND COMPANY
    Inventors: William B. Brasso, David J. Turner, Susan M. Kircher, Fatimah Alrashidi-Brooks
  • Patent number: 12173332
    Abstract: A new mutant of D-amino acid transaminase, based on supercomputing-assisted technology, belongs to the fields of computational biology, computer-aided design, and enzyme engineering technology, and specifically relates to mutants of D-amino acid transaminase obtained based on supercomputing-assisted technology and applications thereof. Compared to the wild-type enzyme, the aforementioned mutant of D-amino acid transaminase exhibits a half-life (t1/2) of over 12 hours at 40° C., while it is only 8.8 minutes for the wild-type D-amino acid transaminase. The half-inactivation temperature (T5015) of the mutant is 45.3° C., approximately 5.4° C. higher than that of the wild-type D-amino acid transaminase. This substantially enhances its thermal stability, enzymatic activity, etc., effectively broadening its application fields and scope. The mutant has a wide range of industrial applications and thus holds substantial practical value.
    Type: Grant
    Filed: July 26, 2023
    Date of Patent: December 24, 2024
    Assignee: SHANDONG COMPUTER SCIENCE CENTER (NATIONAL SUPERCOMPUTER CENTER IN JINAN)
    Inventors: Xin Wang, Ming Yang, Xiaoming Wu, Fuqiang Wang, Yan Liang, Zhenya Chen, Chao Mu
  • Patent number: 12173049
    Abstract: Provided herein, inter alia, are compositions and methods for culturing mammalian cells. In certain aspects, the composition is a medium containing one or more of a lithium ion source, one or more fatty acids, and/or ethanol. Use of any of the cell culture media described herein to culture cells that have been genetically engineered to produce one or more recombinant polypeptides (for example, antibodies) can result in increased titers, a more favorable glycosylation profile, and/or modulated (e.g. decreased) amounts of high and low molecular weight species, and/or modulated (e.g. decreased) amounts of acidic or basic charge variants, compared to cells cultured in a medium that does not contain one or more of a lithium ion source, one or more fatty acids, and/or ethanol.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: December 24, 2024
    Assignee: La Jolla Biologics, Inc.
    Inventors: Christopher T. Leber, Michael W. Y. Shen, Yiwen Tao, Hugh Eugene Murray, IV
  • Patent number: 12168041
    Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an arylsulfatase A (ASA) protein, salt, and a polysorbate surfactant for the treatment of Metachromatic Leukodystrophy Disease.
    Type: Grant
    Filed: March 24, 2020
    Date of Patent: December 17, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Nazila Salamat-Miller, Katherine Taylor, Paul Campolieto, Zahra Shahrokh, Jing Pan, Lawrence Charnas, Teresa Leah Wright, Pericles Calias
  • Patent number: 12121569
    Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an iduronate-2-sulfatase (I2S) protein, salt, and a polysorbate surfactant for the treatment of Hunters Syndrome.
    Type: Grant
    Filed: January 18, 2022
    Date of Patent: October 22, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Gaozhong Zhu, Kris Lowe, Zahra Shahrokh, James Christian, Richard Fahrner, Jing Pan, Teresa Leah Wright, Pericles Calias
  • Patent number: 12084650
    Abstract: Provided is a composition for preserving cell-free nucleic acids and/or cells in a biological sample and methods for use thereof. The composition comprises at least one volume excluding polymer, at least one osmotic agent and at least one enzyme inhibitor. The composition optionally further comprises at least one metabolic inhibitor. Further, provided is a kit comprising the composition, preferably in a blood collection tube, or the components of the composition.
    Type: Grant
    Filed: April 20, 2023
    Date of Patent: September 10, 2024
    Assignee: Norgen Biotek Corp.
    Inventors: Taha Alexander Haj-Ahmad, Yousef Haj-Ahmad
  • Patent number: 12084677
    Abstract: Described herein are methods of recellularizing an organ or tissue matrix.
    Type: Grant
    Filed: July 6, 2022
    Date of Patent: September 10, 2024
    Assignee: Regents of the University of Minnesota
    Inventors: Doris Taylor, Stefan M. Kren
  • Patent number: 12048722
    Abstract: Described herein are methods and compositions for using microbial agents (probiotics) and agents that promote growth of certain microbes (prebiotics) for management (including prevention and treatment) of musculoskeletal disorders, including osteoporosis, osteopenia, Paget's disease, stunting, osteoarthritis, osteomyelitis, and delayed or non-union fractures.
    Type: Grant
    Filed: July 29, 2022
    Date of Patent: July 30, 2024
    Assignee: Solarea Bio, Inc.
    Inventors: Gerardo V. Toledo, Maria Juliana Soto-Giron, Jinwoo Kim, Julie E. Button, Eric Michael Schott
  • Patent number: 12024704
    Abstract: Compositions including metal nano- and/or micro-particles in solution with photosynthetic bioproduct producing microorganisms. These light harvesting complexes increase growth rates and photosynthetic efficiency of the constituent microorganisms, reducing the light required for a specific production level, or increases production for a specific light level. Compositions including zero-valent iron nanoparticles (nZVIs) in solution with photosynthetic bioproduct producing microorganisms. The nZVIs cause increased growth, lipid production and fatty acid production.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: July 2, 2024
    Assignee: Morgan State University
    Inventors: Viji Sitther, Somayeh Fathabad
  • Patent number: 12023412
    Abstract: Disclosed is a dissolvable, gel-forming film, and methods for its use, comprising a water-soluble cellulose ether, a hydrophilic rheological modifying agent, and an active proteolytic enzyme or other drug substance. The gel-forming film has a water content of less than 15% w/w and is capable of forming a hydrogel when contacted with water or other aqueous medium. The disclosed films achieve delivery of stable proteolytic enzymes to the desired site of action in a manner that provides uniform delivery of the enzymes.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: July 2, 2024
    Assignee: SMITH & NEPHEW, INC.
    Inventors: Lei Shi, Aleksa Jovanovic, Dennis Carson
  • Patent number: 12016907
    Abstract: Disclosed is a hydrogel comprising a hydrophilic gelling agent that includes a nonionic cellulose ether, and active thermolysin, wherein the proteolytic activity of the thermolysin does not decrease by more than 20% when stored at room temperature for 6 months.
    Type: Grant
    Filed: August 15, 2022
    Date of Patent: June 25, 2024
    Assignee: SMITH & NEPHEW, INC.
    Inventors: Lei Shi, Aleksa Jovanovic, Dennis Carson
  • Patent number: 12011476
    Abstract: The present invention generally relates to systems and methods for treating certain oxidative stress conditions. In one aspect, compositions and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, a subject having pulmonary fibrosis. In some embodiments, an inhibitor of ERp57 (for example, thiomuscimol) and/or an inhibitor of GSTP (for example, TLK-199) may be used to treat the subject. Also provided in certain aspects of the present invention are kits for such therapies, methods for promoting such therapies, and the like.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: June 18, 2024
    Assignee: The University of Vermont and State Agricultural College
    Inventors: Yvonne M. Janssen-Heininger, Vikas Anathy